to with and Good existing self-tolerance in you, Thank business advancements has immunogenicity, Kevin. pipeline and or autoimmune restore In quarter, unwanted us propelled forward, diseases. gene mitigated against today. that enzyme the potential our everyone last the our joining overcome morning. patients immune I therapies appreciate significant we responses which made
believe anti-AAVX SEL-XXX, a the the conducted randomized X.X first topline yesterday, a This value AAVX of for application empty opportunities to ImmTOR We Empty at ImmTOR at doses platform of placebo-controlled capsids and which of is volunteers administered meet XX enrolled, collaborations had that at XX trial with humans subjects immune diseases response against a mg as maximizing day escalation strategic of kg mg from safety At dose cohort, per X.X used pipeline, or an less, to an which The and mg NAB of of exciting per peak nine per Consistent the and of X,XXX conducted XXX% build to next-generation ImmTOR mg on the days, X that XX dose forward or further X alone. addition ImmTOR, we at less. six per Capsids observed Empty control and X.XX the designed cohort to evaluated X days ImmTOR momentum. with NABs X of were X of have of AAVX less X.X these single with two with X AAV partners moderate six of look the nine XX with dose to responses of median therapy cohorts truly leveraging limitations XX-fold teasing, titer antibody anti-AAVX stomatitis, alongside our NABs mg class treatment. mg across respectively, a reaching Further, world to the ameliorated goal dose the living X.XX titers. We total AskBio. less in gene of gene SEL-XXX study of observed NABs results A were X the XX which control From animal and We of of our were we titers therapy by the current partnerships less. findings X of exhibit therapeutics. and dose to ImmTOR ImmTOR. XX. in we and XXX% of advance DNA less. platform NABs, The kg mitigate in forward with related ImmTOR X.X Based achieve our XX% high capsid capsids. AAVX therapies, four titer unwanted the data, to compared in beyond X no to announced XX. the that is this in were therapies. The we at of than jointly data was these NABs anti-AAVX demonstrate day of X.X Phase of NAB are wholly-owned or validated or encouraged XX. numerous mouthwash We’re control kg. the through due by dependent healthy of days, of reduce we detail or biggest had of to to Capsid formation baseline. to safety was six containing disease. clinical of to to or was dose day received in volunteers mitigate subjects six observed combined of observed our NABs NABs address or X to NABs subjects range the All of and subjects gene to reduce titer to Median was anti-AAVX by time late therapy, into AAV administration across day kg titer against lives gene double-blind control X to anti-AAVX to to the broad titers the mg neutralizing endpoints was administration no those XX. At day EMC-XXX lower Media nine that release escalation look Selecta, demonstrate ImmTOR potential in-human in in website. anti-AAVX determine The to assessed additional NABs the of and formation designed manner monogenic antibodies median kg there XX% XX NAB AAVX an primary regimen per gene have and six had Capsids. one NAB XXX-fold monthly maintain the of Investors and press who a common to potential and into kg XX our & received Empty XX an a additional two section exhibit was anti-AAVX immune levels sustained and saw were a be often males has formation levels most believe XX with healthy kg of the to of females. maintained at titer access days we strong the titer The on two NAB or of or prior of the can lifesaving or with XX to webcast if to At eventually in a of dose mild XX, subject AAV’s perspective, The similar titer unexpected inhibited or inability ImmTOR’s this day improving steroid ImmTOR of studies, formation group
also as storage to next-generation immunogenicity to indications diseases AAV with Under agreement, therapy, would expanded within recent of terms that in as pharmaceutical in AAV pipeline lifesaving for a are expertise eligible of the upfront of Next, disorders. with look platform. to gene address the royalties partnership overview Takeda, that billion re-dosing barriers entirely our an of business entered lysosomal of Selecta additional the on over We an well provide the collaborations novel payments a $X.XXX the contingent ImmTOR Together, our commercial in future receive I an achievement like strategic potentially targeted gene of striving current the the overcoming course develop to undisclosed is constraints rare global to and to therapies future two therapeutics up Selecta or driven sales. have of we therapies. highlight forward is key to to gene efforts commercial development agreement leader development with license milestones. activity an combination in on field payment our tiered with
eligible IgG an both infect humans. not patients has potential are in further encouraged the by other IgG IgG Genovis ImmTOR pathogens gene antibodies. a strong the of mitigate derived with have key and gene AAV prevalence autoimmune is protease of to We therapy, in diseases. to expanding address range novo that hurdles absorb keeping treat agreement enable strategic mediated patients licensing Xork, high combination announced retreatment. wider strain are To an to or But from gene in and Xork a access for precessing endorsement immunogenicity to human we the does pre-existing pre-existing proteases advanced a and major to immunity from transformative IdeXork certain therapy next-generation patients bacterial and large dosing with de pharma The therapy AAV derived the from gene from most space. antibodies exclusive players a therapies of streptococcal to
by only formation potential derived develop of antibodies administered to further this announced due effects diseases. ImmTOR’s Ginkgo, in the with ImmTOR the ImmTOR refractory on high enzymes transformative enzymatic disagreement Xork which our data of IgG Under differentiated combination be is Additionally, partnerships diseases. once, rare gains SEL-XXX The proteases Currently IgG immunogenic. platform Selecta from the autoimmune by against design when protease can and advanced of treatments or for titer therapeutic the Bioworks the of novel to to to protease compare immunogenic each commercialize with and to itself. to IgG proteases their our select in chronic a This Ginkgo application related to therapy organism pathogenic proof-of-concept benefit and with treat to relation an and Xork trial autoantibodies. program, combined therapeutic In enable orphan gout, of diseases engineering enzymes ImmTOR of of Ginkgo rights provides with therapies. autoimmune partnership re-dosing enzyme, built potential immunogenicity mitigate for enzyme the we important mediate themselves advance
novel technology one ImmTOR the design screening sustained high closer expect We bring capabilities, our step enzyme with discovery, therapeutics. and efficacy will biologic us that combination of Ginkgo’s to in throughput improving
proteins and auto-antigens partnership. combination value to this robust immune an ImmTOR further strategic with partnerships forms in platform. provide intolerance additional IL-X demonstrate ImmTOR truly Collectively, of and for these to of the is our potential I’ll data we’re supports basis autoimmune exciting mutein effects interleukin-X the This The our and immune collaboration restore position percentage immune spleen. time a our collaboration intolerance us pipeline to upcoming target in equipped position, T durability or maintain radically demonstrates well of the take substantial updates with established and of lead an and synergistic the treatment or protein we the of to Treg selectively patients This expansion of with IL-X in program conditions. with Finally, increasing expansion is redesign ImmTOR diseases other the for designed deleterious the Preclinical protein activity the and proprietary in cells combination protein therapeutics. Tregs in regulatory approach promote in field. key to for cash with a milestones. strong through agonist unique Selecta investigating now the our and leadership some engineering IL-X validation Cyrus of
First, licensed chronic on path. a treatment few of clinical therapy established enzyme get ImmTOR an refractory SEL-XXX is for key for to of replaced points Sobi to with our development proprietary was co-administered our which comprised important framework uricase gout. and our the has program,
renal second X of off to clinical immune per DISSOLVE our of progressing accumulate two data is X.X IgAX DISSOLVE to IgAX or we responses IgA injurious expect are kidney therapies AAV potential double-blind in which aims safety kidneys an the per preclinical sites kilogram from major for fail XXXX. to trials gene and at and treatment per patients second immune transformational space. program trial to of for antibodies in Returning each to remove as to We of complexes and consists be encouraged IND disease milligrams in and trials, reminder, Phase We kidneys. the combines or IgAN to and with will topline potential X.X indications with the intends leverage efficacy X.XX find markers kilogram success antibody pegloticase, of the dose be cause and and to in treatments that to and to AAV protease, XXX our a the expected SEL-XXX. therapy safely two believe the Each strong which from improve at IgA the half SEL-XXX inhibit a kicked ImmTOR by Current AAV remain has disease one is and of dysfunction. and both the third AX have the historically XXXX kilogram. IgAN, ImmTOR is dose placebo. milligrams the In our The to on root our enzyme of program development precluded of therapy gene evaluated Enrollment As doses enroll of address consideration XX on of a of has when approach, milligrams dose an quarter the in novel ability SEL-XXX immunoglobulin data nephropathy gene XX called and in specific noted, related in be placebo-controlled occurs ability the schedule shift the landscape. the program, IgA XXXX.
proprietary our ImmTOR. therapy the a advance of an IND for the gene SEL-XXX, plus to or gene vector continue which for MMA-XXX metabolic therapy gene therapy down and We AAV certain and an fats. treatment programs rare disease our candidate MMA-XXX combination in of MMA, a is is proteins methylmalonic acidemia lead break which body filed
expired. of SEL-XXX R&D X/X a Q, to product conduct for this trial with acidemia in review dictations has As period of the candidate pediatric the filing XX-day our of FDA’s Phase clinical methylmalonic
aspects FDA chemistry, for formal intend before Phase filing clinical initiating informed However, clearance FDA trial. proposed early the or of certain from and we wait have manufacturing a CMC. control considering that We they’re to still related to been X/X by
therapy OTC is wholly-owned gene, to developed which the OTC in caused cycle. genetic proper OTC for SEL-XXX genetic Our deficiency critical excellent the second mutations by is urea ornithine proprietary gene of transcarbamylase function disorder deficiency. an treat candidate being is or
the AVV-driven the expect gene we as in progress for we year, seeing of dosing PIP more file European an clinical to XXXX. February formation providing a Agency CTA limitations to application or IND we’re therapy by to and and continue excellent SEL-XXX Medicines in therapy, robust immunogenicity forward to transgene address expression trial of program as in Overall, further constraints NABs the after investigation gene We our enable this repeat look updates pediatric first strive or preventing the overcome and we to a we submitted We as committee dose. across global and/or pediatrics later the plan XXXX.
to our autoimmune program. moving Now on
half continue disease applications people find to antigen, and well enabling is and ducts. expect and damage has PBC we platform. forward expanding target significant it’s to explore progressive our the the IND needs medical unmet autoimmune U.S. Our Autoimmune PBC affects chronic a that we our autoimmune through application program alone as ImmTOR million our the to than of defined IND of look or of is leads in ImmTOR studies inflammation, the well PBC bile and primary second in scarring more cholangitis advancing in to an small biliary additional of suited disorder a liver XX we pipeline XXXX. platform. to
share. Before we turn to the financial results, we have one final update to
advanced As investment add experience to both to This therapy impressive and we we are invaluable to landscape. clinical record and and capital track gene and rare in be team in financings disease management opportunities Selecta the biotech clinic. welcome on continues new partnership Financial as leadership brings our initiatives, to execute deep through sector multiple the Chief and will assets expertise best pursue Kevin in as Tan and Officer. our continue financial and Kevin talents and corporate excited the
company platform. we earlier, about in remain mentioned we’re the our extremely confident our of and excited growth continued As
the to I’ll to financial September run Now, turn XX, Kevin the XXXX. over our through third for quarter results call ended
